209 related articles for article (PubMed ID: 28379285)
1. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
Ma B; King AD; Leung L; Wang K; Poon A; Ho WM; Mo F; Chan CML; Chan ATC; Wong SCC
Ann Oncol; 2017 Jul; 28(7):1576-1581. PubMed ID: 28379285
[TBL] [Abstract][Full Text] [Related]
2. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
[TBL] [Abstract][Full Text] [Related]
4. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
Liu FY; Yen TC; Wang JY; Yang TS
Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
[TBL] [Abstract][Full Text] [Related]
5. Early
Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
[TBL] [Abstract][Full Text] [Related]
6. Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy.
Hendlisz A; Golfinopoulos V; Garcia C; Covas A; Emonts P; Ameye L; Paesmans M; Deleporte A; Machiels G; Toussaint E; Vanderlinden B; Awada A; Piccart M; Flamen P
Ann Oncol; 2012 Jul; 23(7):1687-93. PubMed ID: 22112970
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
[TBL] [Abstract][Full Text] [Related]
9. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of metabolic response with
Segreto S; Fonti R; Ottaviano M; Pellegrino S; Pace L; Damiano V; Palmieri G; Del Vecchio S
Cancer Imaging; 2017 Mar; 17(1):10. PubMed ID: 28264726
[TBL] [Abstract][Full Text] [Related]
11. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: a lesion-based and patient-based analysis.
Chiu KWH; Lam KO; An H; Cheung GTC; Lau JKS; Choy TS; Lee VHF
BMC Cancer; 2018 Jul; 18(1):776. PubMed ID: 30064385
[TBL] [Abstract][Full Text] [Related]
15. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
16. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
Jimbo M; Andrews JR; Ahmed ME; Dundar A; Karnes RJ; Bryce AH; Kendi AT; Kwon ED; Lowe VJ; Bold MS
Prostate; 2022 Jan; 82(1):41-48. PubMed ID: 34633087
[TBL] [Abstract][Full Text] [Related]
18. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
[TBL] [Abstract][Full Text] [Related]
19. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
Delgado-Ureña M; Ortega FG; de Miguel-Pérez D; Rodriguez-Martínez A; García-Puche JL; Ilyine H; Lorente JA; Exposito-Hernandez J; Garrido-Navas MC; Delgado-Ramirez M; Serrano MJ
J Transl Med; 2018 Sep; 16(1):251. PubMed ID: 30189880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
